期刊
MOLECULES
卷 27, 期 17, 页码 -出版社
MDPI
DOI: 10.3390/molecules27175359
关键词
c-Met inhibitors; tepotinib; chiral compounds; kinase; cancer
资金
- Foundation of Guangdong Basic and Applied Basic Research [2019A1515110266]
- Foundation for Young Talents [2019KQNCX159]
- Jiangmen Program for Young Talents [2019td04]
A series of tepotinib derivatives with two chiral centers were designed and synthesized as anticancer agents. Among them, the optimal compound (R, S)-12a exhibited strong antiproliferative activity against MHCC97H cell lines by inhibiting c-Met activation and the downstream AKT signaling pathway, suppressing wound closure, inducing cellular apoptosis, and arresting cell cycle at the G(1) phase in a dose-dependent fashion.
A series of tepotinib derivatives with two chiral centers was designed, synthesized, and evaluated as anticancer agents. The optimal compound (R, S)-12a strongly exhibited antiproliferative activity against MHCC97H cell lines with an IC50 value of 0.002 mu M, compared to tepotinib (IC50 = 0.013 mu M). Mechanistic studies revealed that compound (R, S)-12a significantly inhibited c-Met activation, as well as the downstream AKT signaling pathway, and suppressed wound closure. Moreover, compound (R, S)-12a induced cellular apoptosis and cell cycle arrest at the G(1) phase in a dose-dependent fashion.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据